Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer’s Disease: Secondary Analyses from the A4 Study - 21/11/24
, P. Maruff 3, 4, D.M. Rentz 1, 2, M.C. Donohue 5, A. Liu 5, P.S. Aisen 5, R.A. Sperling 1, 2A4 Study Team
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Primary results from the Anti-Amyloid in Asymptomatic Alzheimer’s disease Study (A4) suggested no benefit of solanezumab on its primary cognitive outcome, a composite of paper and pencil tests (the Preclinical Alzheimer’s Cognitive Composite; PACC).
Objective |
To determine whether change in cognitive performance, assessed using the Computerized Cognitive Composite (C3) summary score and C3 individual tests, differed between treatment groups over 240 weeks, differed based on baseline Aβ burden, and tracked with PACC decline.
Design |
Longitudinal analysis of cognitive change over 240 weeks on the C3 Summary Score and C3 individual tests between participants randomly assigned to solanezumab at a dose of up to 1600 mg intravenously every 4 weeks versus placebo.
Setting |
The A4 study took place at 67 sites in Australia, Canada, Japan and the United States.
Participants |
Cognitively unimpaired older adults (n=1117, Mean Age=71.9, 60.7% female) with elevated brain amyloid levels on 18F-florbetapir positron-emission tomography (PET) at baseline (n=549 in the solanezumab group; n=568 in the placebo group).
Measurements |
Participants completed the C3 battery and PACC every 6 months. The C3 Summary Score combines the Cogstate Brief Battery (CBB)-One Card Learning, the Behavioral Pattern Separation (BPS) Test- Object- Lure Discrimination Index, and the Face Name Associative Memory Exam (FNAME)- Face-Name Matching.
Results |
Change on the C3 Summary Score was moderately correlated with change on the PACC (Spearman’s corr=0.53, 95% CI: 0.49 to 0.57; p<0.001). At 240 weeks, mean change in the C3 Summary Score did not differ between groups; +0.24 in the solanezumab group and +0.27 in the placebo group (mean difference= −0.02; 95% CI: −0.13 to 0.08; p = 0.650). Lack of a treatment effect was similarly observed across most individual C3 tests. Performance on the C3 tests were influenced by level of amyloid burden, where higher levels were associated with worse performance.
Conclusion |
This study provides corroborating evidence that solanezumab does not slow cognitive decline in preclinical AD as exhibited with a computerized cognitive assessment with some evidence that solanezumab may exacerbate cognition on select digital outcomes. This study also provides important information that amyloid related cognitive change manifests differently on individual C3 tests.
Le texte complet de cet article est disponible en PDF.Key words : Solanezumab, preclinical Alzheimer’s disease, clinical trial, digital cognitive assessment, computerized cognitive assessment
Plan
Vol 11 - N° 4
P. 846-856 - août 2024 Retour au numéro
Article précédent
- Longitudinal Trajectories of the Cognitive Function Index in the A4 Study
- Rebecca E. Amariglio, J.D. Grill, D.M. Rentz, G.A. Marshall, M.C. Donohue, A. Liu, P.S. Aisen, R.A. Sperling, A4 Study team
- Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical Trial
- Roy Yaari, K.C. Holdridge, M. Mancini, M.S. Rafii, M. Case, C. Battioui, J.R. Sims, P.S. Aisen, R.A. Sperling, A4 Study Team
Bienvenue sur EM-consulte, la référence des professionnels de santé.